Our News

14 August 2025

NanoCell Therapeutics Wins EU Funding for Breakthrough CAR-T Cancer Therapy Development

Read more...

29 July 2025

NanoCell Announces Publication of Research Data in Journal for ImmunoTherapy of Cancer Demonstrating First-in-Class Non-Viral DNA-Based In Vivo CAR-T Generation

Read more...

16 June 2025

NanoCell Secures Seed-Extension Financing from The Institute for Follicular Lymphoma Innovation to Advance Lead Clinical Candidate for B Cell Malignancies

Read more...

4 February 2025

NanoCell Therapeutics Announces Upcoming Participation in Investor Conferences

Read more...

8 November 2024

NanoCell Therapeutics Announces Animal Proof of Concept Data Demonstrating Non-viral DNA Delivery for In Vivo CAR-T Cell Generation

Read more...

22 October 2024

NanoCell Therapeutics Announces Upcoming Participation in Investor and Scientific Conferences

Read more...

16 May 2024

NanoCell Therapeutics Inc. and OneChain Immunotherapeutics S.L Announce Collaboration on In Vivo CAR-T Therapy for B-cell Lymphoma

Read more...

19 March 2024

NanoCell Therapeutics Inc. Appoints Charles F. Albright, PhD, to its Scientific Advisory Board

Read more...

26 September 2023

NanoCell Therapeutics Inc. Appoints Dr. Jacek Lubelski, PhD as Chief Technology Officer

Read more...

3 August 2023

NanoCell Therapeutics Inc. Appoints Florence Salmon, PhD to its Scientific Advisory Board

Read more...

4 January 2023

NanoCell Theapeutics Inc, in Consortium with Leading Research Organizations, Secures Multimillion Euro HORIZON-EIC Pathfinder Challenges Grant for Pioneering Gene Therapy Platform

Read more...